Such strategic options will likely involve Allergan asking for an out-sized price for its top-selling Botox. Botox could face challenges from Revance’s (RVNC) RT002 botulin offering which has shown promise in clinical trials. Revance is also expected to partner with Mylan to create a biosimilar for Botox. Now Shocking The Street, an investment service the Shock Exchange runs in conjunction with Seeking Alpha, is reporting Japan is asking for steep discounts on Botox pricing. Such price cuts, in addition to pending competition, could kills Allergan’s strategic options.